OmniAb, Inc. OABI
Biotechnology: Commercial Physical & Biological Resarch · IPO 2021 · data as of November 13, 2026
OmniAb, Inc. (OABI) is a healthcare company listed in the US with a market value of about $716M. In the twelve months to September 30, 2026 it had revenue of $40M and net income of -$43M, a net margin of -108.1%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 300.9, a 5-year average ROIC of -16%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 96% below the current price.
About OmniAb
OmniAb is listed in the US and classified in biotechnology: commercial physical & biological resarch, IPO year 2021. Revenue went from $35M in 2021 to $19M in 2025, a decline of about 14.4% a year. It was profitable in 0 of the last 5 years in our data. Its share count rose by 33% over three years (dilution for shareholders). It spends 256% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Positive free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 5 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | $40M | $19M | $26M | $34M | $59M | $35M |
| Net income | -$43M | -$65M | -$62M | -$51M | -$22M | -$27M |
| Free cash flow | $2M | -$37M | -$42M | $703000 | -$21M | -$10M |
| EPS (diluted) | $-0.34 | $-0.57 | $-0.61 | $-0.51 | $-0.26 | $-0.33 |
| Net margin | -108.1% | -347.0% | -235.0% | -148.2% | -37.8% | -77.8% |
| ROIC | — | -23.4% | -20.8% | -16.1% | -6.2% | -11.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $8.33, 70% above the current price; targets range from $5.00 to $12.00; the consensus rating is “Strong buy”; expected EPS is $-0.35 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is OmniAb stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 96% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does OmniAb pay a dividend?
Not currently.
Is OmniAb a good stock to buy?
We do not give buy or sell advice. OmniAb scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.